On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam Roy & Shipra Gandhi Roswell Park Comprehensive Cancer Center The approved
MoreBy Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center The CDK 4/6 inhibitors with endocrine therapy are the current standard of care for first-line treatment
MoreBy Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for patients with
MoreBy Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Attainment of pathological complete response (pCR) of breast cancer is associated with improved long-term outcomes (event-free survival and overall survival) compared to
MoreBy Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
MoreOn March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patients with early, hormone receptor (HR)-positive, human epidermal growth factor receptor
MoreOn February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and
MoreOn January 27, 2023, the U.S. Food and Drug Administration approved elacestrant for postmenopausal, non-pregnant women and adult men with advanced or metastatic ER-positive HER-2 negative breast cancer. Patients must have received
MoreBy Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors
More